TMAO in Patients With Severe Aortic Stenosis (TASTE)

Medical University of Warsaw

Status: Unknown

Conditions: Heart Failure; Aortic Stenosis

Treatments: Diagnostic Test: Measurement of plasma and urine trimethylamine-N-oxide concentration

Study type: Observational

Funder types: Other

Identifiers

NCT04406805

KB/211/2018

Details and patient eligibility

About

Trimethylamine N-oxide (TMAO) has recently gained increasing scientific interest in the field of cardiovascular disease, including its role in cell protection against osmotic and hydrostatic stress. Aortic stenosis (AS) is the most common valvular heart disease, affecting about 7.6 million people over 75 years of age in North America and Europe alone. We hypothesized that TMAO plays a role in protection of the cardiomyocytes against pressure overload in patients with AS. The primary aim of this study is to assess the correlation between the serum and urine TMAO concentration, and (i) echocardiographic, (ii) biochemical and (iii) histopathological parameters of heart failure in patients with severe AS. The secondary aim of this study is to evaluate a correlation between the baseline TMAO concentrations and the post-treatment clinical status, as well as the post-treatment echocardiographic and biochemical parameters.

Enrollment: 70 estimated patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Informed consent to participate in the study
• Severe aortic stenosis, defined as aortic valve area <1.0 cm2 or aortic valve area index <0.6 cm2/m2 as calculated by the continuity equation on transthoracic echocardiography, regardless of the transvalvular gradient, with or without coexisting symptoms of heart failure
• Qualification for surgical aortic valve replacement or transcatheter aortic valve implantation by the Heart Team in accordance with European Society of Cardiology guidelines

Exclusion criteria

• Heart failure of etiology other than aortic stenosis
• Coexisting, haemodynamically significant aortic regurgitation
• Myocardial infarction within the last 3 months
• Coronary revascularization within the last month or planned during transcatheter aortic valve implantation or surgical aortic valve replacement
• Chronic kidney disease with estimated glomerular filtration rate <45 ml/min/1.73 m2
• Acute gastrointestinal disease within the last month
• Active neoplastic disease
• Chronic inflammatory disease
• Autoimmune disease
• Chronic intestinal disease
• Antibiotic therapy within the last 2 months
• Dietary supplements within the last 7 days

Trial design

70 participants in 1 patient group

Severe aortic stenosis

Description:

Patients will be enrolled among those who will be (i) aged from 18 to 99 years, (ii) admitted to the hospital due to severe aortic stenosis, and (iii) qualified for treatment with either surgical aortic valve replacement or transcatheter aortic valve implantation

Treatment:

Diagnostic Test: Measurement of plasma and urine trimethylamine-N-oxide concentration